This Article Full Text Full Text (PDF) All Versions of this Article: 106/13/1729    most recent 01.CIR.0000029749.16101.44v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suda, O. Articles by Nakashima, Y. Search for Related Content PubMed PubMed Citation Articles by Suda, O. Articles by Nakashima, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE ACRIDINE NITRIC OXIDE Medline Plus Health Information Coronary Artery Disease Related Collections Endothelium/vascular type/nitric oxide

(Circulation. 2002;106:1729.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Long-Term Treatment With N-Nitro-L-Arginine Methyl Ester Causes Arteriosclerotic Coronary Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice

Osamu Suda, MD; Masato Tsutsui, MD, PhD; Tsuyoshi Morishita, MD; Akihide Tanimoto, MD, PhD; Masataka Horiuchi, MD; Hiromi Tasaki, MD, PhD; Paul L. Huang, MD, PhD; Yasuyuki Sasaguri, MD, PhD; Nobuyuki Yanagihara, PhD; Yasuhide Nakashima, MD, PhD

From the Second Department of Internal Medicine (O.S., M.T., T.M., M.H., H.T., Y.N.) and the Departments of Pharmacology (M.T., N.Y.) and Pathology (A.T., Y.S.), University of Occupational and Environmental Health, Kitakyushu, Japan, and the Cardiovascular Research Center (P.L.H.), Harvard Medical School, Boston, Mass.

Correspondence to Yasuhide Nakashima, MD, PhD, The Second Department of Internal Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. E-mail mt2498{at}med.uoeh-u.ac.jp

Background— N-nitro-L-arginine methyl ester (L-NAME) is widely used to inhibit endothelial synthesis of NO in vivo. However, it is controversial whether the long-term vascular effects of L-NAME are mediated primarily by inhibition of endothelial NO synthesis. We addressed this point in mice that are deficient in the endothelial NO synthase gene (eNOS-KO mice).

Methods and Results— Wild-type and eNOS-KO mice received L-NAME in drinking water for 8 weeks. In wild-type mice, long-term treatment with L-NAME caused significant medial thickening and perivascular fibrosis in coronary microvessels but not in large coronary arteries. Importantly, in eNOS-KO mice, treatment with L-NAME also caused an extent of medial thickening and perivascular fibrosis in coronary microvessels that was comparable to that in wild-type mice and that was not prevented by supplementation of L-arginine. Vascular NO and cGMP levels were not significantly reduced by L-NAME treatment, and no expression of inducible or neuronal NO synthase was noted in microvessels of eNOS-KO mice, suggesting an involvement of NO-independent mechanisms. Treatment with L-NAME caused an upregulation of vascular ACE and an increase in cardiac lucigenin chemiluminescence that were comparable in both strains and that were abolished by simultaneous treatment with temocapril (ACE inhibitor) or CS866 (angiotensin II type 1 receptor antagonist) along with the suppression of vascular lesion formation.

Conclusions— These results provide the first direct evidence that the long-term vascular effects of L-NAME are not mediated by simple inhibition of endothelial NO synthesis. Direct upregulation of local ACE and increased oxidative stress appear to be involved in the long-term vascular effects of L-NAME in vivo.

Key Words: arteriosclerosis • coronary disease • nitric oxide • nitric oxide synthase

This article has been cited by other articles:

				Y. Feng, M. van Eck, E. Van Craeyveld, F. Jacobs, V. Carlier, S. Van Linthout, M. Erdel, M. Tjwa, and B. De Geest Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer Blood, January 15, 2009; 113(3): 755 - 764. [Abstract] [Full Text] [PDF]

				S. Nakata, M. Tsutsui, H. Shimokawa, O. Suda, T. Morishita, K. Shibata, Y. Yatera, K. Sabanai, A. Tanimoto, M. Nagasaki, et al. Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms Circulation, April 29, 2008; 117(17): 2211 - 2223. [Abstract] [Full Text] [PDF]

				S. Nakata, M. Tsutsui, H. Shimokawa, M. Tamura, H. Tasaki, T. Morishita, O. Suda, S. Ueno, Y. Toyohira, Y. Nakashima, et al. Vascular Neuronal NO Synthase Is Selectively Upregulated by Platelet-Derived Growth Factor: Involvement of the MEK/ERK Pathway Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2502 - 2508. [Abstract] [Full Text] [PDF]

				T. Morishita, M. Tsutsui, H. Shimokawa, K. Sabanai, H. Tasaki, O. Suda, S. Nakata, A. Tanimoto, K.-Y. Wang, Y. Ueta, et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms PNAS, July 26, 2005; 102(30): 10616 - 10621. [Abstract] [Full Text] [PDF]

				S. Iida, G. L. Baumbach, J. L. Lavoie, F. M. Faraci, C. D. Sigmund, and D. D. Heistad Spontaneous Stroke in a Genetic Model of Hypertension in Mice Stroke, June 1, 2005; 36(6): 1253 - 1258. [Abstract] [Full Text] [PDF]

				O. Suda, M. Tsutsui, T. Morishita, H. Tasaki, S. Ueno, S. Nakata, T. Tsujimoto, Y. Toyohira, Y. Hayashida, Y. Sasaguri, et al. Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice: Involvement of Renin-Angiotensin System and Oxidative Stress Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1682 - 1688. [Abstract] [Full Text] [PDF]

				Y. Takemura, K. Fukuo, O. Yasuda, T. Inoue, N. Inomata, T. Yokoi, H. Kawamoto, T. Suhara, and T. Ogihara Fas Signaling Induces Akt Activation and Upregulation of Endothelial Nitric Oxide Synthase Expression Hypertension, April 1, 2004; 43(4): 880 - 884. [Abstract] [Full Text] [PDF]